Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
14 Oct 2020
Historique:
received: 26 08 2020
revised: 06 10 2020
accepted: 08 10 2020
entrez: 17 10 2020
pubmed: 18 10 2020
medline: 20 4 2021
Statut: epublish

Résumé

This study evaluates whether serum phospholipids fatty acids (PL-FAs) and markers of their endogenous metabolism are associated with breast cancer (BC) subtypes. EpiGEICAM is a Spanish multicenter matched case-control study. A lifestyle and food frequency questionnaire was completed by 1017 BC cases and healthy women pairs. Serum PL-FA percentages were measured by gas chromatography-mass spectrometry. Conditional and multinomial logistic regression models were used to quantify the association of PL-FA tertiles with BC risk, overall and by pathological subtype (luminal, HER2+ and triple negative). Stratified analyses by body mass index and menopausal status were also performed. Serum PL-FAs were measured in 795 (78%) pairs. Women with high serum levels of stearic acid (odds ratio (OR)

Identifiants

pubmed: 33066483
pii: nu12103132
doi: 10.3390/nu12103132
pmc: PMC7602197
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Fatty Acids 0
Phospholipids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Sociedad Española de Oncología Médica
ID : (SEOM)
Organisme : Ministerio de Economía y Competitividad
ID : IJCI-2014-20900
Organisme : Fundación Cerveza y Salud
ID : 2005
Organisme : Federación de Asociaciones de Mujeres con Cáncer de Mama
ID : (FECMA)
Organisme : Asociación Española Contra el Cancer
ID : AECC 2006 & 2016

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Nutr Cancer. 2011 Nov;63(8):1235-50
pubmed: 22043987
Public Health Nutr. 2016 Jun;19(8):1457-63
pubmed: 26434699
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Asian Pac J Cancer Prev. 2019 May 25;20(5):1321-1327
pubmed: 31127884
Clin Nutr. 2020 Mar;39(3):755-764
pubmed: 30954361
PLoS One. 2014 Feb 27;9(2):e90442
pubmed: 24587366
Int J Prev Med. 2014 Jan;5(1):6-15
pubmed: 24554986
Curr Opin Lipidol. 2011 Feb;22(1):6-10
pubmed: 20935562
Biochim Biophys Acta. 2016 Dec;1861(12 Pt A):1865-1880
pubmed: 27639967
Gynecol Oncol. 2013 Sep;130(3):609-14
pubmed: 23747837
Nutr Cancer. 2009;61(4):500-9
pubmed: 19838922
J Nutr Metab. 2017;2017:3848201
pubmed: 28781892
Am J Epidemiol. 2008 Jun 1;167(11):1312-20
pubmed: 18390841
Int J Cancer. 2016 Apr 15;138(8):1894-904
pubmed: 26595162
Am J Clin Nutr. 2007 Apr;85(4):1090-7
pubmed: 17413110
Ann Oncol. 2017 Nov 1;28(11):2836-2842
pubmed: 28950350
Adv Exp Med Biol. 2014;824:61-81
pubmed: 25038994
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Biochim Biophys Acta. 2011 Nov;1811(11):648-56
pubmed: 21787881
Nutr Hosp. 2015 Aug 01;32(2):435-77
pubmed: 26268073
PLoS One. 2015 Feb 12;10(2):e0118206
pubmed: 25675445
Biochimie. 2017 Oct;141:107-120
pubmed: 28804001
Int J Cancer. 1999 Nov 26;83(5):585-90
pubmed: 10521790
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Cancer Causes Control. 2016 Jun;27(6):759-73
pubmed: 27146840
Nutr J. 2013 Feb 19;12:26
pubmed: 23421854
Gynecol Oncol. 2017 Mar;144(3):577-585
pubmed: 28057355
Ann Oncol. 2019 Oct 1;30(10):1541-1557
pubmed: 31373601
Gac Sanit. 2016 Sep-Oct;30(5):379-82
pubmed: 27266514
Cancer Sci. 2013 Jun;104(6):760-4
pubmed: 23414387
Epidemiology. 1995 Jul;6(4):356-65
pubmed: 7548341
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
Lipids. 2005 Dec;40(12):1193-200
pubmed: 16477802
J Natl Cancer Inst. 2014 Apr 09;106(5):
pubmed: 24718872
Eur J Nutr. 2019 Jun;58(4):1515-1527
pubmed: 29616321
Sci Rep. 2019 Mar 7;9(1):3904
pubmed: 30846706
BMJ. 2013 Jun 27;346:f3706
pubmed: 23814120
Oncotarget. 2017 Apr 25;8(17):29487-29500
pubmed: 28412757
Clin Transl Oncol. 2017 Jul;19(7):799-825
pubmed: 28093701
Eur J Clin Nutr. 2004 May;58(5):761-70
pubmed: 15116079
J Chromatogr A. 2020 May 24;1619:460965
pubmed: 32085913
PLoS One. 2014 Sep 15;9(9):e104083
pubmed: 25222131
J Acad Nutr Diet. 2012 Jul;112(7):1029-41, 1041.e1-15
pubmed: 22889633
Am J Epidemiol. 1985 Jul;122(1):51-65
pubmed: 4014201
Breast Cancer Res Treat. 2013 Jan;137(1):319-27
pubmed: 23208590
Curr Breast Cancer Rep. 2018 Mar;10(1):14-27
pubmed: 30662586
Exp Ther Med. 2018 Feb;15(2):1167-1176
pubmed: 29434704
Eur J Clin Nutr. 2007 Jul;61(7):925-7
pubmed: 17299500
Nutr Cancer. 2009;61(5):746-53
pubmed: 19838949
Br J Cancer. 1987 Oct;56(4):455-8
pubmed: 3689663
Int J Cancer. 2004 Sep 10;111(4):584-91
pubmed: 15239137
Curr Opin Lipidol. 2006 Feb;17(1):22-7
pubmed: 16407712
Am J Clin Nutr. 2014 Mar;99(3):431-5
pubmed: 24429537
Eur J Clin Nutr. 2000 May;54(5):367-72
pubmed: 10822282
Am J Epidemiol. 2013 Oct 15;178(8):1246-55
pubmed: 23989197
J Acad Nutr Diet. 2015 Feb;115(2):324
pubmed: 25636223
Int J Cancer. 2018 Mar 15;142(6):1116-1129
pubmed: 29071721
J Natl Cancer Inst. 2001 Jul 18;93(14):1088-95
pubmed: 11459870
Cancer Causes Control. 2009 May;20(4):497-504
pubmed: 19255861
J Clin Oncol. 2010 Jun 1;28(16):2784-95
pubmed: 20404251
Eur J Cancer Prev. 2017 Sep;26(5):385-395
pubmed: 28746163

Auteurs

Virginia Lope (V)

Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, 28029 Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain.
GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.

Ángel Guerrero-Zotano (Á)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Instituto Valenciano de Oncología, 46009 Valencia, Spain.

Ana Casas (A)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Hospital Universitario Virgen Del Rocio, 41013 Sevilla, Spain.

José Manuel Baena-Cañada (JM)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Hospital Universitario Puerta del Mar, 11009 Cádiz, Spain.
Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), 11009 Cádiz, Spain.

Begoña Bermejo (B)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.
Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.
CIBERONC, ISCIII, 28029 Madrid, Spain.

Beatriz Pérez-Gómez (B)

Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, 28029 Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain.
GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.

Inmaculada Criado-Navarro (I)

Analytical Chemistry Department, Universidad de Córdoba, 14071 Córdoba, Spain.
Maimónides Institute of Biomedical Research (IMIBIC), Reina Sofia University Hospital, University of Córdoba, 14071 Córdoba, Spain.
CIBERFES, ISCIII, 28029 Madrid, Spain.

Silvia Antolín (S)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Medical Oncology Unit, Complejo Hospitalario Universitario A Coruña, 15006 A Coruña, Spain.

Pedro Sánchez-Rovira (P)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Complejo Hospitalario de Jaén, 23007 Jaén, Spain.

Manuel Ramos-Vázquez (M)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Centro Oncológico de Galicia, 15009 A Coruña, Spain.

Antonio Antón (A)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón, 50009 Zaragoza, Spain.

Adela Castelló (A)

Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, 28029 Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain.
Faculty of Medicine, University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain.

José Ángel García-Saénz (JÁ)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Hospital Clínico San Carlos, 28040 Madrid, Spain.

Montserrat Muñoz (M)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Medical Oncology, Hospital Clínic Barcelona, 08036 Barcelona, Spain.
Translational Genomics and Targeted Therapeutics, Institut d'Investigacions Biomèdiques Pi i Sunyer-IDIBAPS, 08036 Barcelona, Spain.

Ana de Juan (A)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Hospital Marqués de Valdecilla, 39008 Santander, Spain.

Raquel Andrés (R)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain.

Antonio Llombart-Cussac (A)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Hospital Arnau de Vilanova, 46015 Valencia, Spain.

Blanca Hernando (B)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Hospital General Yagüe, 09005 Burgos, Spain.

Rosa María Franquesa (RM)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
Hospital General de Vic, 08500 Barcelona, Spain.

Rosalia Caballero (R)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.

Feliciano Priego-Capote (F)

Analytical Chemistry Department, Universidad de Córdoba, 14071 Córdoba, Spain.
Maimónides Institute of Biomedical Research (IMIBIC), Reina Sofia University Hospital, University of Córdoba, 14071 Córdoba, Spain.
CIBERFES, ISCIII, 28029 Madrid, Spain.

Miguel Martín (M)

GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.
CIBERONC, ISCIII, 28029 Madrid, Spain.
Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
Instituto Investigación Sanitaria Gregorio Marañón, Universidad Complutense, 28007 Madrid, Spain.

Marina Pollán (M)

Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, 28029 Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain.
GEICAM Spanish Breast Cancer Group, 28703 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH